Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 12/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 12/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 12/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 12/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 12/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 12/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.33 |
| ▸ | MPO | P05164 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233683 | 0.88 | KDM4E (0.41) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2234658 | 0.88 | PDK1 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2235005 | 0.87 | NOTUM (0.39) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2234771 | 0.86 | NOTUM (0.36) | — | |
| SCHEMBL2237173 | 0.83 | KDM4E (0.35) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2233589 | 0.83 | BRD4 (0.37) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2236393 | 0.83 | HRH3 (0.36) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2235085 | 0.82 | PDK1 (0.45) | — | |
| SCHEMBL2234012 | 0.82 | BUB1 (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2234009 | 0.82 | BUB1 (0.33) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | GABRA1 1783/4885GABRG2 2731/4885GABRB3 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.